Search Results

Genostics will acquire China rights to Oncimmune’s blood-based cancer testing platform in return for a $13.5M investment into the UK-based company’s shares.

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, and its partner, Genostics Company Limited (“Genostics”), today announce the start of a multi-centre case control study on early lung cancer detection

Perennial Real Estate of Singapore announced a $1.2B joint venture to develop hospital-centered mixed-use developments in China.